GlobeNewswire by notified

Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category

Share
  • Idorsia’s dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the category ‘Primary & Speciality’.
  • Each year, the Prix Galien Suisse honors the most innovative new medicines and diagnostics on the Swiss market.

Allschwil, Switzerland – June 21, 2024
Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the ‘Primary & Speciality’ category. The Prix Galien Suisse is awarded annually to the most innovative new medicines and diagnostics on the Swiss market, as judged by a jury of renowned Swiss scientists.

Alice Huisman, General Manager of Idorsia Switzerland and Austria, commented:
"We are very proud to have been awarded the prestigious Prix Galien. The recognition from the jury is a wonderful endorsement of Idorsia's commitment to innovation in Swiss healthcare and the value that the new treatment brings to improving Swiss patient care for chronic insomnia. My team is working to make this medicine accessible to all Swiss patients.”

Martine Clozel, MD and Chief Scientific Officer added: "I am delighted that our innovative research in Switzerland has been recognized with the Prix Galien Suisse 2024. Our research team began working on the science of orexin and orexin receptors immediately after they were first described in 1998. Our initial work led to the understanding that antagonism of the orexin system was the key to increasing sleep while preserving a natural sleep architecture in patients with insomnia. The team set the target to design a dual orexin receptor antagonist that achieved a rapid onset of effect and a duration of action sufficient to cover the totality of the night – with minimal next-morning residual effect – at optimally effective doses. This task proved to be very challenging, and we had to synthesize and characterize more than 25,000 compounds to arrive to the innovative compound now recognized with the Prix Galien Suisse.”

Notes to the editor

About insomnia disorders
Insomnia disorder is defined as difficulty initiating or maintaining sleep, causing clinically significant distress or impairment in important areas of daytime functioning. This impact on sleep quantity or quality should be present for at least three nights per week, over the period of at least three months, and occurs despite an adequate opportunity to sleep.1

Insomnia is a state of overactive wake signals and studies have shown that in patients with insomnia, brain regions associated with wakefulness remain more active during sleep.2,3 Chronic insomnia is a common problem with an estimated prevalence in Switzerland of 9.2% of the working-age population.4

Insomnia as a disorder is distinctly different from a short period of poor sleep and it can affect both physical and mental health.1,5 It is a persistent condition that has a negative impact on daytime performance.1 Idorsia's research has shown that poor sleep quality can affect many aspects of daily life, including the ability to concentrate, mood and energy levels.

The goal of treating insomnia is to improve sleep quality and quantity, as well as daytime performance, while avoiding side and after-effects the next morning. The currently recommended treatment for insomnia includes sleep hygiene, cognitive behavioral therapy and pharmacotherapy.4

About the orexin system
Wake and sleep signaling is regulated by intricate neural circuitry in the brain. One key component of this process is the orexin system, which helps promote wakefulness.6,7 There are two forms of orexin neuropeptides – small protein-like molecules used by nerve cells (neurons) to communicate with each other in the brain – orexin A and orexin B.6,8 Orexin promotes wakefulness through its receptors OX1R and OX2R. 6,8 Together, these neuropeptides and receptors make up the orexin system. The orexin system stimulates targeted neurons in the wake system – leading to the release of several chemicals (serotonin, histamine, acetylcholine, norepinephrine) – to promote wakefulness.9 Under normal circumstances, orexin levels rise throughout the day as wakefulness is promoted and then fall at night.10 Overactivity of the wake system is an important driver of insomnia.7

The Idorsia research team has been studying the science of orexin and orexin receptors since they were first described in 1998. The team's initial work led to the conclusion that antagonism of the orexin system is key to maintaining natural sleep architecture in patients with insomnia. With this goal in mind, the team developed dual antagonists with the aim of a rapid onset of action and a duration of action sufficient to bridge the night but short enough to minimize any negative residual activity the next morning at optimally effective doses.

References

  1. The Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM–5; American Psychiatric Association, 2013).
  2. Buysse, D.J., et al. Drug Discov Today Dis Models. 2011;8(4):129-137.
  3. Levenson, J.C., et al. Chest. 2015;147(4):1179-1192.
  4. Hafner, Marco, et al., 2023. Santa Monica. CA: RAND Corporation.
  5. Wardle-Pinkston S., et al. Sleep Med Rev. 2019;48.
  6. Muehlan, C., et al. J Psychopharmacol. 2020;34(3):326-335.
  7. Boof, M.L., et al. Eur J Clin Pharmacol. 2019;75(2):195-205.
  8. Muehlan, C., et al. Expert Opin. Drug Metab. Toxicol. 2020;16(11):1063–1078.
  9. Clifford, B.S., et al. Trends Neurosci. 2001;24(12).726-31.
  10. Gotter, A.L., et al. BMC Neuroscience. 2013;14(1):14-19.

About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.

For more information please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye